Tesla’s third-quarter earnings call left investors perplexed, CNBC reported, after CEO Elon Musk sidestepped the electric vehicle manufacturer’s fundamentals to discuss robots.
After the closing bell on Oct. 22, Tesla’s Q3 earnings call kicked off.
For publicly traded companies like Tesla, earnings calls are quarterly conferences during which a company’s principal figures disclose financial performance, strategies, and other matters related to the firm’s operations and cash flow.
It’s no secret that, after several years of consumer loyalty and profitability, the once-beloved Tesla has seen its sales suffer through a sustained, global slump for much of 2025.
Musk is objectively a major factor in the brand’s stumbles, leading an established Tesla stock booster to surmise that the brand damage inflicted by the CEO’s then-recent actions and statements was beyond fixing.
However, Tesla’s Board of Directors repeatedly and publicly signaled its support for Musk, offering him a massive pay package and lauding his vision as critical to the brand’s continued success.
If investors or the Board anticipated valuable feedback from Musk on salvaging the brand during the Oct. 22 call, they were likely disappointed. Musk “said nothing about demand for the company’s electric vehicles,” according to CNBC, instead focusing on robots and Robotaxis.
Musk first introduced a humanoid robot dubbed Optimus at a 2021 conference. Four years on, Optimus still isn’t market-ready, but Tesla’s CEO seemed convinced it had a future in medicine.
“Optimus will be an incredible surgeon,” Musk began, before claiming that automation will somehow “actually create a world where there is no poverty, where everyone has access to the finest medical care.”
CNBC is a staid financial publication not prone to colorful reporting, but its coverage of Musk’s remarks during Tesla’s Q3 call encapsulated how little it served the brand’s investors.
The outlet focused in part on Tesla’s long-promised Robotaxis.
When Robotaxis finally debuted over the summer after years of hype, the rollout was both limited and beset by technical issues, and CNBC’s skepticism was both evident and backed up by real-world developments.
